Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

ClinicalTrials.gov ID: NCT00063713

Public ClinicalTrials.gov record NCT00063713. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Study identification

NCT ID
NCT00063713
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Enrollment
152 participants

Conditions and interventions

Interventions

  • VELCADE TM (bortezomib) for Injection Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2003
Primary completion
Nov 30, 2005
Completion
Not listed
Last update posted
Feb 10, 2008

Started 2003

United States locations

U.S. sites
35
U.S. states
21
U.S. cities
29
Facility City State ZIP Site status
University of Alabama Birmingham Alabama 35294
Alta Bates Medical Center Berkeley California 94704
City of Hope Comprehensive Cancer Center Duarte California 91010-3000
Loma Linda Cancer Research Institute Loma Linda California 92354
UCLA School of Medicine Los Angeles California 90095
Stanford University Palo Alto California 94304
University of Colorado Cancer Denver Colorado 80262
Georgetown University Medical Center Lombardi Cancer Center Washington D.C. District of Columbia 20007
H. Lee Moffitt Cancer Center & Research Institute Tampa Florida 33612
The Emory Clinic Atlanta Georgia 30322
The Rush Cancer Center Chicago Illinois 60612
University of Chicago Medical Center Chicago Illinois 60637
Indiana University Cancer Center Indianapolis Indiana 46202
University of Iowa Hospital Division Iowa City Iowa 52242
North Memorial Hospital Robbinsdale Minnesota 55422
Onc/Hem Associates of Kansas City Kansas City Missouri 64111
University of Nebraska Medical Center Omaha Nebraska 68198
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03756
Beth Israel Medical Center New York New York 10003
St Lukes-Roosevelt Hospital New York New York 10019
Memorial Sloan Kettering Cancer Center New York New York 10021
New York Hospital Cornell Medical Center New York New York 10021
University of Rochester Medical Center Rochester New York 14642
University of North Carolina Chapel Hill North Carolina 27599
Wake Forest, University health Sciences/Comprehensive Cancer Center Winston-Salem North Carolina 27157
Cancer Care Associates Oklahoma City Oklahoma 73112
Cancer Care Associates Tulsa Oklahoma 74136
Oregon Health Science University Portland Oregon 97239
University of Pennsylvania Cancer Center Philadelphia Pennsylvania 19104
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Western Pennsylvania Hospital Pittsburgh Pennsylvania 15224
Vanderbilt University Nashville Tennessee 37232
Sarah Cannon Cancer Center Nashville Tennessee
MD Anderson Cancer Center Houston Texas 77030
University Hospital-Madison Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00063713, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 10, 2008 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00063713 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →